Transforming ovarian cancer care by targeting minimal residual disease

Amir A Jazaeri; Rachel Grisham; Anne Knisely; Stefani Spranger; Dmitriy Zamarin; R Tyler Hillman; Barrett C Lawson; Kathleen H Burns; Sanghoon Lee; Shannon N Westin; Enrico Moiso; Marc J Williams; Neelkanth M Bardhan; Thomas Pisanic; Ursula Matulonis; Britta Weigelt; IeMing Shih; Panagiotis A Konstantinopoulos; Stephanie Gaillard; Linghua Wang; Carol Aghajanian; Alan D D'Andrea; Paula Hammond; Sohrab Shah; Kai W Wucherpfennig; Karen H Lu

doi:10.1016/j.medj.2023.08.004

Transforming ovarian cancer care by targeting minimal residual disease

Med. 2023 Nov 10;4(11):755-760. doi: 10.1016/j.medj.2023.08.004.

Authors

Amir A Jazaeri¹, Rachel Grisham², Anne Knisely³, Stefani Spranger⁴, Dmitriy Zamarin², R Tyler Hillman³, Barrett C Lawson³, Kathleen H Burns⁵, Sanghoon Lee³, Shannon N Westin³, Enrico Moiso⁴, Marc J Williams², Neelkanth M Bardhan⁶, Thomas Pisanic⁷, Ursula Matulonis⁵, Britta Weigelt², IeMing Shih⁸, Panagiotis A Konstantinopoulos⁵, Stephanie Gaillard⁸, Linghua Wang³, Carol Aghajanian², Alan D D'Andrea⁵, Paula Hammond⁴, Sohrab Shah², Kai W Wucherpfennig⁵, Karen H Lu³

Affiliations

¹ University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: aajazaeri@mdanderson.org.
² Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁵ Dana-Farber Cancer Institute, Boston, MA, USA.
⁶ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Break Through Cancer, Cambridge, MA, USA.
⁷ Break Through Cancer, Cambridge, MA, USA.
⁸ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

PMID: 37951209
DOI: 10.1016/j.medj.2023.08.004

Abstract

Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Ovarian Epithelial / therapy
Female
Humans
Neoplasm, Residual
Ovarian Neoplasms* / drug therapy

Grants and funding

T32 CA101642/CA/NCI NIH HHS/United States